{
  "ticker": "LLY",
  "target_date": "2025-03-31",
  "actual_date": "2025-03-31",
  "collected_at": "2025-12-08T11:34:54.530257",
  "price": {
    "open": 804.37,
    "high": 823.3,
    "low": 784.91,
    "close": 821.2081298828125,
    "volume": 3737000,
    "change_1d_pct": 0.41,
    "change_7d_pct": -1.98,
    "change_30d_pct": -2.17
  },
  "technicals": {
    "rsi_14": 50.63,
    "sma_20": 839.81,
    "sma_50": 838.53,
    "macd": -7.403,
    "macd_signal": -4.64,
    "macd_histogram": -2.763,
    "bb_upper": 910.57,
    "bb_lower": 769.06,
    "price_vs_sma20_pct": -2.22,
    "price_vs_sma50_pct": -2.07,
    "volume_ratio": 1.08
  },
  "fundamentals": {
    "market_cap": 888872697856,
    "pe_ratio": 48.581085,
    "forward_pe": 43.757282,
    "price_to_book": 37.332077,
    "price_to_sales": 14.959201,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.83,
    "pct_from_52w_low": 58.96
  },
  "macro": {
    "spy": {
      "price": 556.2,
      "change_1d_pct": 0.67,
      "change_7d_pct": -0.81
    },
    "vix": {
      "level": 22.28,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.25
    },
    "dollar_index": {
      "level": 104.21
    },
    "gold": {
      "price": 3122.8
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know",
      "source": "Yahoo",
      "datetime": 1743457515,
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=51c11e32ee55710e9e29881813cbb5fa19f626fed2b8d9b7770bbcdb480bc7da"
    },
    {
      "headline": "Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip",
      "source": "Yahoo",
      "datetime": 1743442140,
      "summary": "Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant year-over-year earnings growth. Further bolstering its stock was the announcement of successful Phase 2 results f",
      "url": "https://finnhub.io/api/news?id=96fe43f7185e471142f3db2093a873bcdc04583e90cc5d71687f88fdee8dd74b"
    },
    {
      "headline": "Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%",
      "source": "Yahoo",
      "datetime": 1743439155,
      "summary": "Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodis",
      "url": "https://finnhub.io/api/news?id=4c740a938097d3f3cf5c3d4092faa9fe350ef7ae619a7828a8e2d38d8d80e2ca"
    },
    {
      "headline": "Biotech Stocks Q1 2025 Recap: Winners And Underperformers",
      "source": "SeekingAlpha",
      "datetime": 1743431649,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fca2009a34592e24b4f3882a92027b0a12ab50ad4e5643e6b09744fc6b98a472"
    },
    {
      "headline": "Is the Future Bleak for SAVA Stock Following Another Setback?",
      "source": "Yahoo",
      "datetime": 1743429600,
      "summary": "The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.",
      "url": "https://finnhub.io/api/news?id=7d84c3daf4c126a4152f12fd1ffd0164e0ab8c50603f755bccb5b231201ede9e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}